Helicobacter pylori Eradication Therapy in The Netherlands

References

• European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8–13.
   PubMed Web of Science ®Google Scholar
• Malaty H, El-Zimaity HMT, Genta RM, Cole RA, Graham DY. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 1001–4.
   PubMed Web of Science ®Google Scholar
• de Boer WA, Van Etten R, Schneeberger PM. Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Neth J Med 1998; 52: 10–5.
   PubMed Web of Science ®Google Scholar
• Noach LA, Bertola MA, Schwartz MP, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: an evaluation of various therapeutic trials. Eur J Gastroenterol Hepatol 1994; 6: 585–91.
   Web of Science ®Google Scholar
• Rauws EA, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori [see comments]. Lancet 1990; 335(8700): 1233–5.
   PubMed Web of Science ®Google Scholar
• Veenendaal RA, Pena AS, Meijer JL, et al. Long term serological surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 1291–4.
   PubMed Web of Science ®Google Scholar
• Thijs JC, Van Zwet AA, Moolenaar W, Oom JAJ, De Korte H, Runhaar EA. Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 131–4.
   PubMedGoogle Scholar
• de Boer WA, Driessen WMM, Jansz A, Tytgat GNJ. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345(8953): 817–20.
   PubMed Web of Science ®Google Scholar
• de Boer WA, Driessen WMM, Potters VPJ, Tytgat GNJ. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastro-enterol 1994; 89: 1993–7.
   Google Scholar
• Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934–8.
   PubMed Web of Science ®Google Scholar
• Thijs JC, Van Zwet AA, Moolenaar W, Wolfhagen MJH, Huinink JTB. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996; 91: 93–7.
   Google Scholar
• Van Zwet AA, Thijs JC, Kooistra-Smid AMD, Schirm J, Snijder JAM. Sensitivity of culture compared with that of polymerase chain reaction for detection of Helicobacter pylori from antral biopsy samples. J Clin Microbiol 1993; 31: 1918–20.
   Google Scholar
• Van Zwet AA, Thijs JC, Oom JAJ, Hoogeveen J, Duringshoff BL. Failure to eradicate Helicobacter pylori in patients with metronidazole-resistant strains [2]. Eur J Gastroenterol Hepa-tol 1993; 5: 185–6.
   Google Scholar
• Houben MHMG, Hensen EF, van ‘t Hoff BWM, et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in the treatment of Helicobacter pylori (Hp) in metronidazole resistant or sensitive patients. Gastroenterology 1998; 114: A153 (G0628).
   Google Scholar
• Thijs JC, Van Zwet AA, Thijs WJ, van der Wouden EJ, Kooy A. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997; 11: 305–9.
   PubMedGoogle Scholar
• Van der Hulst RWM, Weel JFL, Van der Ende A, Ten Kate FJW, Dankert J, Tytgat GNJ. Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastro-enterol 1996; 91: 2333–7.
   Google Scholar
• Tan AC, den Hartog G, Meijer JW, Thies JE, de Vries RA, Mulder CJ. No additional value of bismuth subcitrate to combination omeprazole/amoxicillin therapy in the eradication of Helicobacter pylori. Helicobacter 1997; 2: 194–8.
   PubMedGoogle Scholar
• Veenendaal RA, Gotz JM, Meijer JL, et al. Comparison of omeprazole and clarthromycin versus omeprazole, clarithromycin and metronidazole in the treatment of Helicobacter pylori. Gut 1996; 39 Suppl 2: A31.
   PubMedGoogle Scholar
• Witteman EM, Hazenberg BP, Haeck PWE, et al. Comparison of pantoprazole-based dual and triple therapies for H. pylori eradication: effects on symptoms in nonulcer dyspepsia patients. Gut 1997; 41 Suppl 3: A199–A200.
   Google Scholar
• de Boer WA, Van Etten RJXM, Schade RWB, et al. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 109–12.
   PubMedGoogle Scholar
• de Boer WA, Etten RJXM. Weekend lansoprazole-quadruple therapy for Helicobacter pylori infection. Gut 1997; 41 Suppl 1: A97.
   Google Scholar
• de Boer WA, Van Etten R, Coremans A, Schneeberger PM. Two-day ‘weekend’ lansoprazole-quadruple therapy for elicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 77–81.
   PubMedGoogle Scholar
• de Boer SY, Siem TH. Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1119–21.
   PubMedGoogle Scholar
• de Boer WA, Van Etten RJX, Schade RWB, Ouwehand ME, Schneeberger PM, Tytgat GNJ. Four-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am J Gastroenterol 1996; 91: 1778–82.
   PubMedGoogle Scholar
• de Boer WA, Van Etten FJXM, Lai JYL, Schneeberger PM, van de Wouw AM, Driessen WMM. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori Infection. Helicobacter 1996; 1: 145–50.
   PubMedGoogle Scholar
• de Boer wA, Driessen WMM, Jansz AR, Tytgat GNJ. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepa-tol 1995; 7: 1189–94.
   PubMedGoogle Scholar
• Vanderhulst RWM, Vanderende A, Homan A, Roorda P, Dankert J, Tytgat GNJ. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998; 42: 166–9.
   PubMedGoogle Scholar
• de Boer WA, Haeck PWE, Otten MH, Mulder CJ. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomised comparison between two 7-day triple therapies and a 14-day dual therapy. Eur J Gastroenterol Hepatol 1997; 9: A44.
   Google Scholar
• Kolkman JJ, Tan TG, Oudkerk Pool M, et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1123–9.
   PubMedGoogle Scholar
• Van der Wouden EJ, Thijs JC, Van Zwet AA, Kooy A, Kleibeuker JH. One week triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) vs two week dual therapy with RBC and CLA for H. pylori (Hp) infection: results of a randomized controlled trial [Abstract]. Spring meeting of The Netherlands Society of Gastroenterology 1998.
   Google Scholar
• Van der Wouden EJ, Thijs JC, Kooy A, Kleibeuker JH. Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H. pylori (Hp) infection [Abstract]. Spring meeting of The Netherlands Society of Gastroenterology 1998.
   Google Scholar
• Graham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori. Basic mechanisms to clinical cure. Dordrecht: Kluwer Academic Publishers. In press.
   Google Scholar
• Schmid CH, Ross SD, Whiting GW, Cory D, Chalmers TC. Omeprazole plus antibiotics in the eradication of H. pylori infection: a meta-regression [Abstract 4A: 29]. Gut 1996; 39 Suppl 2: A37.
   Google Scholar
• Pan ZJ, van der Hulst RW, Feller M, et al. Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 1997; 35: 1344–7.
   PubMedGoogle Scholar
• Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 1990; 58: 603–10.
   Google Scholar
• Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338(8763): 332–5.
   PubMed Web of Science ®Google Scholar
• Van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082–6.
   PubMed Web of Science ®Google Scholar
• van Doorn LJ, Quint W, Schneeberger P, Tytgat GNJ, de Boer WA. The only good Helicobacter pylori is a dead Helicobacter pylori [letter; comment]. Lancet 1997; 350(9070): 71–2.
   Google Scholar